The start-up is making antivirals and cancer drugs for Big Pharma—and working to treat reproductive problems on its own ...

Pfizer (PFE) stock is in focus as the company exceeds Street forecasts with its Q3 2025 results thanks mainly to its COVID ...

Pfizer and Novo Nordisk's fight for obesity drug developer Metsera ratcheted up on Tuesday, as both companies submitted ...

Pfizer reported lower third-quarter profit as demand for its Covid-19 vaccine and antiviral drug continued to decline.

Pfizer on Tuesday raised its full-year profit forecast for the second quarter in a row as robust demand for its blockbuster ...

And despite the sales slump in the U.S. this past quarter, Pfizer’s Prevnar dynasty still leads in pediatric pneumococcal vaccination worldwide and among conjugated pneumococcal vaccines for adults in ...

Pfizer hiked its full-year profit guidance, citing its strong business performance and cost cuts, even as sales for the ...

Pfizer's Q3 results are due on Nov. 4, with analysts eyeing $16.6B in sales and EPS of 66 cents as investors weigh the ...

Pfizer posts Q3 earnings beat and raises EPS guidance, but weaker COVID product sales weigh on overall revenue momentum.

A fierce US$10 billion bidding war for the Nasdaq-listed anti-obesity drug maker Metsera has resulted in Pfizer emerging with ...

Patients with autoimmune and rheumatic diseases who received antiviral therapy for COVID-19 demonstrated reduced incidence of ...